🇺🇸 FDA

Intelligence Platform

Patents

Browse 912 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10123529

Compounds for protection of cells

Sulfateq B.V. · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10117899

Delivery methods and compositions for nuclease-mediated genome engineering in hematopoieti

Sangamo Therapeutics, Inc. · Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10105392

Isolated renal cells and uses thereof

inRegen · Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10106620

Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10098847

Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid

EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10100279

In vitro production of medial ganglionic eminence precursor cells

The Regents of the University of California · Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10093899

Genetically-modified cells comprising a modified human T cell receptor alpha constant regi

Precision BioSciences, Inc. · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10093900

Genetically-modified cells comprising a modified human T cell receptor alpha constant regi

Precision BioSciences, Inc. · Granted Tue Oct 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10087232

Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy

Protalix Ltd. · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10080730

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

United Therapeutics Corporation · Granted Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10077442

Bioactive renal cells

inRegen · Granted Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10076545

Pharmaceutically compatible method for purifying intact bacterial minicells

EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10077424

Methods of producing RPE cells and compositions of RPE cells

Astellas Institute for Regenerative Medicine · Granted Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10072243

Derivation of embryonic stem cells and embryo-derived cells

Astellas Institute for Regenerative Medicine · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10071123

Treatment of pulmonary arterial hypertension with mesenchymal stem cells

United Therapeutics Corporation · Granted Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10058572

Placenta-derived multipotent stem cells

The Regents of the University of California · Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10052363

Mesenchymal stem cells for the treatment of CNS diseases

BRAINSTORM CELL THERAPEUTICS LTD. · Granted Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10046010

Methods of generating mesenchymal stem cells which secrete neurotrophic factors

BRAINSTORM CELL THERAPEUTICS LTD. · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10046012

Multipotent postnatal stem cells from human periodontal ligament and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10041936

Neuronal cells cultured on microparticles and methods of using same

The Regents of the University of California · Granted Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10034916

Methods of treating a retinal disease by retinal pigment epithelial stem cells

REGENERATIVE RESEARCH FOUNDATION · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10035823

Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflamma

The Regents of the University of California · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10023879

Minimal volume reprogramming of mononuclear cells

Fate Therapeutics, Inc. · Granted Tue Jul 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10016463

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progeni

United Therapeutics Corporation · Granted Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted